Bill
HB 3799
Overview: HB 3799 - Relating to medical treatments with investigational products.Status: In committee upon adjournment.Introduced: March 05, 2025Purpose and Intent: The bill aims t
Overview: HB 3799 - Relating to medical treatments with investigational products.
Status: In committee upon adjournment.
Introduced: March 05, 2025
Purpose and Intent: The bill aims to expand access to investigational medical treatments for terminally ill patients. It seeks to provide these patients with the opportunity to try experimental drugs, biologics, and devices that have not yet received full FDA approval, but have passed initial safety trials.
Key Provisions:
- Allows terminally ill patients, with the consent of their physician, to access investigational treatments that have completed phase 1 clinical trials
- Prohibits state regulatory boards from taking disciplinary action against physicians for recommending or providing access to these investigational products
- Requires informed consent from patients and provides liability protections for healthcare providers
Affected Parties and Impacts:
- Terminally ill patients who may benefit from access to experimental treatments
- Healthcare providers, including physicians, who can now offer these investigational options without fear of disciplinary action
- Pharmaceutical and medical device companies developing new treatments
Procedural and Timeline Considerations:
The bill is currently in committee upon adjournment. If passed, it would take effect immediately upon the Governor's signature.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
